Tobira Therapeutics Inc. (NASDAQ:TBRA) shares traded up 3.3% on Monday . The company traded as high as $4.77 and last traded at $4.74, with a volume of 82,490 shares changing hands. The stock had previously closed at $4.59.

A number of research analysts have recently commented on TBRA shares. HC Wainwright reissued a “buy” rating and set a $31.00 target price (up from $22.00) on shares of Tobira Therapeutics in a research report on Saturday, August 13th. Cowen and Company reissued a “buy” rating and set a $11.00 target price on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Friday, July 29th. Finally, Cantor Fitzgerald cut shares of Tobira Therapeutics to a “buy” rating and set a $19.00 target price on the stock. in a research report on Monday, July 25th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $16.75.

The company’s market cap is $89.21 million. The stock’s 50 day moving average is $4.61 and its 200-day moving average is $8.02.

Tobira Therapeutics (NASDAQ:TBRA) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The firm earned $1.06 million during the quarter. Equities analysts predict that Tobira Therapeutics Inc. will post ($2.65) EPS for the current fiscal year.

In other news, major shareholder A/S Novo sold 59,067 shares of the company’s stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total value of $709,985.34. Following the transaction, the insider now owns 1,914,541 shares in the company, valued at approximately $23,012,782.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.20% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of TBRA. Franklin Resources Inc. purchased a new position in Tobira Therapeutics during the first quarter worth approximately $4,797,000. State Street Corp increased its position in Tobira Therapeutics by 184.3% in the first quarter. State Street Corp now owns 42,875 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 27,794 shares in the last quarter. Geode Capital Management LLC increased its position in Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 799 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Tobira Therapeutics during the second quarter worth approximately $263,000. Finally, California State Teachers Retirement System increased its position in Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 12,951 shares in the last quarter. Institutional investors own 62.02% of the company’s stock.

About Tobira Therapeutics

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

5 Day Chart for NASDAQ:TBRA

Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.